Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Deferred Tax Liability: 2022-2024

Historic Non-Current Deferred Tax Liability for Cartesian Therapeutics (RNAC) over the last 3 years, with Dec 2024 value amounting to $16.1 million.

  • Cartesian Therapeutics' Non-Current Deferred Tax Liability rose 1.82% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.1 million, marking a year-over-year increase of 1.82%. This contributed to the annual value of $16.1 million for FY2024, which is 63.34% down from last year.
  • Per Cartesian Therapeutics' latest filing, its Non-Current Deferred Tax Liability stood at $16.1 million for FY2024, which was down 63.34% from $44.0 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Non-Current Deferred Tax Liability registered a high of $44.0 million during FY2023, and its lowest value of $3.3 million during FY2022.
  • For the 3-year period, Cartesian Therapeutics' Non-Current Deferred Tax Liability averaged around $21.1 million, with its median value being $16.1 million (2024).
  • Per our database at Business Quant, Cartesian Therapeutics' Non-Current Deferred Tax Liability surged by 1,252.47% in 2023 and then tumbled by 63.34% in 2024.
  • Over the past 3 years, Cartesian Therapeutics' Non-Current Deferred Tax Liability (Yearly) stood at $3.3 million in 2022, then soared by 1,252.47% to $44.0 million in 2023, then slumped by 63.34% to $16.1 million in 2024.